Epinephrine pre-filled syringe - Adamis Pharmaceuticals

Drug Profile

Epinephrine pre-filled syringe - Adamis Pharmaceuticals

Alternative Names: Epinephrine injection PFS - Adamis Pharmaceuticals; Epinephrine PFS - Adamis Pharmaceuticals; Symjepi

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Class Antiarrhythmics; Antihaemorrhagics; Antihypotensives; Bronchodilators; Catecholamines; Ethanolamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Anaphylaxis

Most Recent Events

  • 29 Nov 2017 Preregistration for Anaphylaxis (In adolescents, In children) in USA (Parenteral, 0.15mg)
  • 15 Jun 2017 Registered for Anaphylaxis in USA (Parenteral, 0.3mg)
  • 15 Jun 2017 Adamis Pharmaceuticals announces intention to submit NDA to US FDA for smaller sized pre-filled syringe containing epinephrine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top